[go: up one dir, main page]

HN2011002261A - Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3 - Google Patents

Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3

Info

Publication number
HN2011002261A
HN2011002261A HN2011002261A HN2011002261A HN2011002261A HN 2011002261 A HN2011002261 A HN 2011002261A HN 2011002261 A HN2011002261 A HN 2011002261A HN 2011002261 A HN2011002261 A HN 2011002261A HN 2011002261 A HN2011002261 A HN 2011002261A
Authority
HN
Honduras
Prior art keywords
cyclopropilamide
directed against
histamine
receiver
derivatives directed
Prior art date
Application number
HN2011002261A
Other languages
English (en)
Inventor
Andrew Griffin
Original Assignee
Astrazenca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42631518&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2011002261(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazenca Ab filed Critical Astrazenca Ab
Publication of HN2011002261A publication Critical patent/HN2011002261A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

EN LA PRESENTE INVENCION SE DIVULGA AL MENOS UN DERIVADO DE CICLOPROPILAMIDA, AL MENOS UNA COMPOSICION FARMACEUTICA QUE COMPRENDE AL MENOS UN DERIVADO DE CICLOPROPILAMIDA DE LOS AQUI DIVULGADOS Y AL MENOS UN METODO PARA UTILIZAR AL MENOS UN DERIVADO DE CICLOPROPILAMIDA AQUI DIVULGADO PARA EL TRATAMIENTO DE AL MENOS UNA AFECCION VINCULADA AL RECEPTOR H3 DE LA HISTAMINA.
HN2011002261A 2009-02-20 2011-08-19 Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3 HN2011002261A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15406709P 2009-02-20 2009-02-20

Publications (1)

Publication Number Publication Date
HN2011002261A true HN2011002261A (es) 2014-07-31

Family

ID=42631518

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2011002261A HN2011002261A (es) 2009-02-20 2011-08-19 Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3

Country Status (39)

Country Link
US (3) US8993577B2 (es)
EP (1) EP2398780B1 (es)
JP (2) JP5666480B2 (es)
KR (1) KR20110126628A (es)
CN (2) CN104398516A (es)
AR (1) AR075531A1 (es)
AU (1) AU2010216454B2 (es)
BR (1) BRPI1007817A2 (es)
CA (1) CA2752796A1 (es)
CO (1) CO6400219A2 (es)
CR (1) CR20110447A (es)
CU (2) CU20110161A7 (es)
DK (1) DK2398780T3 (es)
DO (1) DOP2011000270A (es)
EA (2) EA020093B1 (es)
EC (1) ECSP11011280A (es)
ES (1) ES2416464T3 (es)
HK (1) HK1208348A1 (es)
HN (1) HN2011002261A (es)
HR (1) HRP20130579T1 (es)
IL (1) IL214277A (es)
ME (1) ME01619B (es)
MX (1) MX2011008280A (es)
NI (1) NI201100160A (es)
NZ (1) NZ595248A (es)
PE (2) PE20151281A1 (es)
PL (1) PL2398780T3 (es)
PT (1) PT2398780E (es)
RS (1) RS52851B (es)
SA (1) SA110310136B1 (es)
SG (1) SG173449A1 (es)
SI (1) SI2398780T1 (es)
SM (1) SMT201300077B (es)
SV (1) SV2011004008A (es)
TW (1) TW201039825A (es)
UA (1) UA108841C2 (es)
UY (1) UY32460A (es)
WO (1) WO2010096011A1 (es)
ZA (1) ZA201106821B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
SG173312A1 (en) * 2006-06-23 2011-08-29 Abbott Lab Cyclopropyl amine derivatives as histamin h3 receptor modulators
WO2009024823A2 (en) * 2007-08-22 2009-02-26 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
MX2012009473A (es) * 2010-02-18 2012-09-12 Astrazeneca Ab Procesos para preparar derivados de ciclopropilamidas e intermedios asociados con estas.
MX2012009537A (es) * 2010-02-18 2012-08-31 Astrazeneca Ab Formas solidas que comprenden un derivado de ciclopropilamida.
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
HUE057460T2 (hu) 2016-03-22 2022-05-28 Merck Sharp & Dohme Nikotinos acetilkolin receptorok alloszterikus modulátorai
WO2022059779A1 (ja) 2020-09-18 2022-03-24 大日本住友製薬株式会社 アミン誘導体
CN114790186A (zh) * 2021-01-25 2022-07-26 武汉人福创新药物研发中心有限公司 作为ep4拮抗剂的稠环化合物及其制备方法和用途

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297170A (es) * 1963-04-04 1900-01-01
NL128365C (es) 1963-11-05
US3449427A (en) * 1965-06-03 1969-06-10 Smithkline Corp Aminocyclopropane derivatives of 5h-dibenzo(a,d)cycloheptenes
US3697506A (en) 1970-08-07 1972-10-10 Pfizer Crystalline alkali metal salts of {60 -carboxybenzylpenicillin and process therefor
US3686335A (en) * 1970-12-21 1972-08-22 Smith Kline French Lab 5-vinyl-5h-di benzo(a,d)cycloheptenes
US4432987A (en) 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
US4547505A (en) 1983-03-25 1985-10-15 Degussa Aktiengesellschaft N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production
CS244821B2 (en) 1983-06-16 1986-08-14 Boehringer Ingelheim Ltd Production method of new substituted phenylalkyl(piperazinyl or homopiperazinyle)-prpylureas or thioureas
DE3418167A1 (de) 1984-05-16 1985-11-21 Bayer Ag, 5090 Leverkusen Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen heteroaryloxyacetamiden
DE3600288A1 (de) 1986-01-08 1987-07-16 Bayer Ag Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonylharnstoff-derivaten
DE3618004A1 (de) 1986-05-28 1987-12-03 Bayer Ag Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonyliso(thio)-harnstoff-derivaten
JPH05503517A (ja) 1989-12-18 1993-06-10 バージニア・コモンウェルス・ユニバーシティ シグマレセプターリガンド及びその用途
US5112818A (en) * 1989-12-29 1992-05-12 Banyu Pharmaceutical Co., Ltd. 2-(2-cyclopropylpyrrolidin-4-ylthio)carbapenhem derivatives
IL102909A0 (en) 1991-08-22 1993-01-31 Monsanto Co Safening herbicidal pyarazolylsulfonylureas
DE4131139A1 (de) 1991-09-19 1993-03-25 Bayer Ag Verfahren zur herstellung von 1-fluor-cyclopropan-1-carbonsaeure
DE122005000055I2 (de) 1993-03-12 2008-06-05 Upjohn Co Kristallines ceftiofur (freie säure)
CN1088062C (zh) 1994-11-23 2002-07-24 纽罗根公司 某些4－氨基甲基－2－取代的咪唑衍生物2－氨基甲基－4－取代的咪唑衍生物新的一族多巴胺受体亚型特异性配体
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5859246A (en) 1997-01-30 1999-01-12 Neurogen Corporation 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands
WO1998037077A1 (en) 1997-02-24 1998-08-27 Zymogenetics, Inc. Calcitonin mimetics
US6160134A (en) 1997-12-24 2000-12-12 Bristol-Myers Squibb Co. Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
BR9907300A (pt) 1998-01-27 2000-10-24 Aventis Pharm Prod Inc Inibidores do fator xa oxoaza-heterociclila substituìdos
US6268367B1 (en) 1998-02-23 2001-07-31 Zymogenetics, Inc. Piperazine derivatives for treating bone deficit conditions
WO2000000492A1 (en) 1998-06-26 2000-01-06 Chugai Seiyaku Kabushiki Kaisha FINE POWDER OF L-α-AMINOADIPIC ACID DERIVATIVE, ORAL SOLID PREPARATIONS CONTAINING THE SAME, AND METHOD FOR TREATMENT OF BULK POWDERS
WO2000040572A1 (en) 1999-01-08 2000-07-13 Neurogen Corporation 1-phenyl-4-(1-[2-aryl]cyclopropyl) methylpiperazines: dopamine receptor ligands
US6284761B1 (en) * 1999-01-08 2001-09-04 Neurogen Corporation 1-phenyl-4-(1-[2-aryl]cyclopropyl)methylpiperazines: dopamine receptor ligands
EP1186604A4 (en) 1999-06-16 2002-10-23 Takeda Chemical Industries Ltd Benzazepine derivatives, process for the preparation of the same and uses thereof
AU7715300A (en) 1999-09-27 2001-04-30 Merck & Co., Inc. Method of preventing osteoporosis
CZ20022332A3 (cs) 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
US6521619B2 (en) * 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
AU2001268724B2 (en) 2000-06-29 2005-06-16 Abbott Laboratories Aryl phenycyclopropyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
JP2004525071A (ja) 2000-07-20 2004-08-19 ニューロジェン コーポレイション カプサイシン受容体リガンド
US6888012B2 (en) 2000-12-25 2005-05-03 Ajinomoto Co., Inc. Process for producing optically active halohydrin compound
SI1379520T1 (sl) * 2001-02-23 2006-08-31 Merck & Co Inc N-substituirani nonaril-heterociklicni NMDA/NR2B antagonisti
JP2005502623A (ja) 2001-07-02 2005-01-27 ノボ　ノルディスク　アクティーゼルスカブ 置換ピペラジンおよびジアゼパン
US7262185B2 (en) 2001-08-08 2007-08-28 Takeda Chemical Industries Ltd. Benzazepine derivative, process for producing the same, and use
CA2457642C (en) 2001-09-26 2009-01-06 Merck & Co., Inc. Crystalline forms of ertapenem sodium
AU2002363236A1 (en) 2001-10-30 2003-05-12 Millennium Pharmaceuticals, Inc. Compounds, pharmaceutical compositions and methods of use therefor
US6861432B2 (en) * 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
BR0308525A (pt) 2002-03-22 2005-02-01 Lg Life Sciences Ltd Formas cristalinas
WO2003103666A2 (en) 2002-06-07 2003-12-18 Altana Pharma Ag Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones
US20040077618A1 (en) * 2002-10-22 2004-04-22 Bennani Youssef L. Cycloalkylamides and their therapeutic applications
US20040209858A1 (en) * 2002-10-22 2004-10-21 Bennani Youssef L. Cycloalkylamides and their therapeutic applications
JPWO2004046110A1 (ja) 2002-11-15 2006-03-16 アステラス製薬株式会社 メラニン凝集ホルモン受容体拮抗剤
JP2006514950A (ja) 2002-12-13 2006-05-18 スミスクライン ビーチャム コーポレーション Ｃｃｒ５拮抗薬としてのシクロプロピル化合物
CA2523431A1 (en) 2003-04-23 2004-11-25 Glaxo Group Limited Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
CA2524321A1 (en) 2003-05-01 2004-11-18 Bristol-Myers Squibb Company Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
ATE464286T1 (de) 2003-12-15 2010-04-15 Japan Tobacco Inc Cyclopropanderivate und ihre pharmazeutische verwendung
ATE537830T1 (de) 2004-07-06 2012-01-15 Xenon Pharmaceuticals Inc Nicotinamid derivate und ihre verwendung als therapeutika
TW200621760A (en) 2004-09-09 2006-07-01 Mitsubishi Pharma Corp 2-morpholino-4-pyrimidone compound
EP1805164B9 (en) 2004-09-29 2011-09-07 Mitsubishi Tanabe Pharma Corporation 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors
HRP20080227T3 (hr) 2004-10-15 2008-06-30 Glaxo Group Limited Pirolidinski derivati kao ligandi histaminskih receptora
BRPI0517423A (pt) 2004-12-27 2008-10-07 Astrazeneca Ab composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
EP1844052A1 (en) 2005-01-26 2007-10-17 Pharmacia & Upjohn Company LLC Thieno[2,3-d]pyrimidine compounds as inhibitors of adp-mediated platelets aggregation
US7790758B2 (en) 2005-02-15 2010-09-07 Glaxo Group Limited Compounds which potentiate glutamate receptor and uses thereof in medicine
KR101063663B1 (ko) 2005-02-17 2011-09-07 아스텔라스세이야쿠 가부시키가이샤 피리딜 비방향족 질소 함유 헤테로환-1-카르복실산에스테르유도체
JP2008534488A (ja) 2005-03-25 2008-08-28 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 血小板凝集阻害剤としての４−ピペラジニルチエノ［２，３−ｄ］ピリミジン化合物
WO2006103544A2 (en) 2005-03-28 2006-10-05 Pharmacia & Upjohn Company Llc 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
WO2006103545A1 (en) 2005-03-28 2006-10-05 Pharmacia & Upjohn Company Llc 4-piperazinylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors
CA2602538A1 (en) 2005-03-28 2006-10-05 Pharmacia & Upjohn Company Llc 4-piperazinothieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
WO2007011623A1 (en) 2005-07-15 2007-01-25 Schering Corporation Quinazoline derivatives useful in cancer treatment
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
CA2606004A1 (en) 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
ATE463481T1 (de) * 2005-09-16 2010-04-15 Janssen Pharmaceutica Nv Cyclopropylamine als modulatoren des histamin-h3- rezeptors
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
BRPI0618076A2 (pt) 2005-10-31 2011-08-16 Janssen Pharmaceutica Nv processos para a preparação de derivados de ciclopropil-amida
JP2009524591A (ja) 2005-12-21 2009-07-02 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとしての複素環誘導体
US8119668B2 (en) 2005-12-23 2012-02-21 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
BRPI0707916A2 (pt) * 2006-01-13 2011-05-17 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem e uso destes compostos
CN101384581B (zh) 2006-02-17 2013-09-18 弗·哈夫曼-拉罗切有限公司 作为5ht2/d3调节剂的苯甲酰基-哌啶衍生物
WO2007098536A1 (en) 2006-03-01 2007-09-07 Cementech Pty Ltd Matrix for masonry elements and method of manufacture thereof
JP2009132621A (ja) 2006-03-13 2009-06-18 Ajinomoto Co Inc シクロプロピルアミド化合物の製造方法
JP2009530390A (ja) 2006-03-23 2009-08-27 アムゲン インコーポレイティッド １−フェニルスルホニル−ジアザ複素環アミド化合物およびヒドロキシステロイドデヒドロゲナーゼ調節因子としてのその使用
WO2007138928A1 (ja) 2006-05-26 2007-12-06 Kaneka Corporation 光学活性３－アミノ－２－ヒドロキシプロピオン酸シクロプロピルアミド誘導体およびその塩の製造方法
SG173312A1 (en) * 2006-06-23 2011-08-29 Abbott Lab Cyclopropyl amine derivatives as histamin h3 receptor modulators
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
WO2008003702A2 (en) 2006-07-03 2008-01-10 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Fused bicyclic compounds interacting with the histamine h4 receptor
US20090247499A1 (en) 2006-08-21 2009-10-01 Fletcher Joan M Sulfonylated piperazines as cannabinoid-1 receptor modulators
TW200828371A (en) 2006-09-21 2008-07-01 Matsushita Electric Industrial Co Ltd Chip-type filter
DE102006056526A1 (de) 2006-11-30 2008-06-05 Archimica Gmbh Verfahren zur stereoselektiven Synthese von chiralen Epoxiden durch ADH-Reduktion von alpha-Abgangsgruppen-substituierten Ketonen und Cyclisierung
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
WO2008147864A2 (en) * 2007-05-22 2008-12-04 Xenon Pharmaceuticals Inc. Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
EP2150115B1 (en) 2007-05-23 2013-09-18 Merck Sharp & Dohme Corp. Cyclopropyl pyrrolidine orexin receptor antagonists
DE602008002598D1 (en) * 2007-06-11 2010-10-28 Hoffmann La Roche Cyclohexylderivate
WO2009024823A2 (en) * 2007-08-22 2009-02-26 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
ES2460897T3 (es) 2007-10-04 2014-05-14 F. Hoffmann-La Roche Ag Derivados de ciclopropil aril amida y usos de los mismos
AR070107A1 (es) 2008-01-15 2010-03-17 Lilly Co Eli R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia
DE102008049371A1 (de) 2008-03-06 2009-09-10 Mühlbauer Ag Einrichtung mit einem RFID-Transponder in einem elektrisch leitfähigen Gegenstand und Herstellungsverfahren hierfür
US8691804B2 (en) 2008-05-08 2014-04-08 Evotec Ag Azetidines and cyclobutanes as histamine H3 receptor antagonists
CN102137836B (zh) 2008-07-28 2015-08-26 赛丹思科大学 用于治疗代谢疾病的化合物
CN101462980B (zh) 2009-01-05 2013-01-09 扬州天辰精细化工有限公司 2，6—二氟苯甲酰胺的工业化生产方法
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
MX2012009537A (es) * 2010-02-18 2012-08-31 Astrazeneca Ab Formas solidas que comprenden un derivado de ciclopropilamida.
MX2012009473A (es) * 2010-02-18 2012-09-12 Astrazeneca Ab Procesos para preparar derivados de ciclopropilamidas e intermedios asociados con estas.

Also Published As

Publication number Publication date
AU2010216454B2 (en) 2013-05-02
MX2011008280A (es) 2011-08-24
HK1164863A1 (en) 2012-09-28
ZA201106821B (en) 2012-06-26
PE20151281A1 (es) 2015-10-04
UY32460A (es) 2010-09-30
NI201100160A (es) 2012-03-15
IL214277A (en) 2015-08-31
IL214277A0 (en) 2011-09-27
CA2752796A1 (en) 2010-08-26
SI2398780T1 (sl) 2013-08-30
DOP2011000270A (es) 2012-08-31
AU2010216454A1 (en) 2011-08-25
SG173449A1 (en) 2011-09-29
US8993577B2 (en) 2015-03-31
EP2398780A4 (en) 2012-09-19
ES2416464T3 (es) 2013-08-01
CU20110161A7 (es) 2012-02-15
US20150164889A1 (en) 2015-06-18
NZ595248A (en) 2014-01-31
SMT201300077B (it) 2013-09-06
ECSP11011280A (es) 2011-09-30
HRP20130579T1 (en) 2013-07-31
SV2011004008A (es) 2012-01-06
EA201490268A1 (ru) 2015-07-30
CU20140013A7 (es) 2014-04-24
JP5666480B2 (ja) 2015-02-12
EP2398780A1 (en) 2011-12-28
TW201039825A (en) 2010-11-16
CR20110447A (es) 2011-09-19
SA110310136B1 (ar) 2014-01-14
PT2398780E (pt) 2013-06-25
CN104398516A (zh) 2015-03-11
CN102405213B (zh) 2014-11-19
ME01619B (me) 2014-09-20
US20100216812A1 (en) 2010-08-26
EP2398780B1 (en) 2013-04-17
AR075531A1 (es) 2011-04-06
JP2015071634A (ja) 2015-04-16
KR20110126628A (ko) 2011-11-23
PL2398780T3 (pl) 2013-08-30
PE20120063A1 (es) 2012-03-04
UA108841C2 (ru) 2015-06-25
CO6400219A2 (es) 2012-03-15
EA201190140A1 (ru) 2012-03-30
WO2010096011A1 (en) 2010-08-26
HK1208348A1 (en) 2016-03-04
US20150164888A1 (en) 2015-06-18
DK2398780T3 (da) 2013-07-01
BRPI1007817A2 (pt) 2017-05-30
EA020093B1 (ru) 2014-08-29
RS52851B (sr) 2013-12-31
JP2012518634A (ja) 2012-08-16
CN102405213A (zh) 2012-04-04

Similar Documents

Publication Publication Date Title
HN2011002261A (es) Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3
DK2411395T3 (da) Furopyrimidindionderivater som modulatorer for TRPA1
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
CO6351794A2 (es) Anticuerpos biespecificos anti-vegf/anti-ang-2
CR20120215A (es) Anticuerpos contra csf-1r humano y usos de los mismos
EA201200486A1 (ru) Лечение онкологических заболеваний
HN2011001247A (es) Inhibidores de cinana akt y p70 s6
CR11623A (es) Compuestos
ECSP11011387A (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
HN2011001021A (es) Combinacion de una insulina y un agonista de glp-1
ECSP12011793A (es) Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, método para la preparación de los mismos y composición farmacéutica que los contiene
ECSP10010018A (es) Derivados de ciclopropilamida
HN2010002582A (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
HN2011001019A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk) produccion y uso de los mismos como productos medicinales
GT201300258A (es) Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa
GT201100322A (es) Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a
BR112012009310A2 (pt) composto, e, composição farmacêutica
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
ECSP099754A (es) Derivados de la espirociclopropil piperidina
CR11765A (es) Derivados de iminopiridina y su uso
ECSP099561A (es) Formulación de nevirapina de liberación prolongada
ES2415029R1 (es) Composición farmacéutica y método para inhibir la producción o amplificar la eliminación de la proteína P24.
UA106886C2 (uk) Спосіб одержання 1-бензил-3-гідроксиметил-1h-індазолу і його похідних та проміжні сполуки магнію
UY31487A1 (es) Derivados de pirazol como inhibidores de 5-lo
UY31335A1 (es) Tratamiento de sintomas vasomotores